中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
11期
78-79
,共2页
尿激酶%瑞替普酶%静脉溶栓%急性心肌梗死
尿激酶%瑞替普酶%靜脈溶栓%急性心肌梗死
뇨격매%서체보매%정맥용전%급성심기경사
Reteplase%Urokinase%Intravenous thrombolysis%Acute myocardial infarction
目的：探讨分析瑞替普酶静脉溶栓在治疗急性心肌梗死(AMI)中的临床治疗效果与安全性。方法选择在2012年7月—2014年6月期间,该院收治的全部符合标准的心肌梗死患者151例,按随机原则分为观察组75例和对照组76例,对照组患者使用药物尿激酶,而对于观察组患者,则给予瑞替普酶静脉溶栓,然后将两组患者的治疗效果进行对比和分析。结果两组患者的冠状动脉再通率对比观察组患者在静脉溶栓后0.5、1 h以及2 h冠状动脉的再通率分别33.5%、66%和88.5%,全部明显高于对照组,差异具有统计学意义(P<0.05)；观察组患者的血清CK以及(CK-MB峰值的时间为(13.58±2.49)、(11.27±2.4)h,较对照组的酶峰值显著提前,但是其差异无统计学的意义(P>0.05)；观察组和对照组患者在静脉溶栓以后4周内死亡率分别为4%和7.89%,该两组患者的死亡率对比,其差异没有统计学的意义(?2=0.267,P>0.05)。结论对于急性心肌梗死患者,使用药物瑞替普酶静脉溶栓,其冠状动脉的再通率高,酶峰值显著提前,而且安全可靠。
目的：探討分析瑞替普酶靜脈溶栓在治療急性心肌梗死(AMI)中的臨床治療效果與安全性。方法選擇在2012年7月—2014年6月期間,該院收治的全部符閤標準的心肌梗死患者151例,按隨機原則分為觀察組75例和對照組76例,對照組患者使用藥物尿激酶,而對于觀察組患者,則給予瑞替普酶靜脈溶栓,然後將兩組患者的治療效果進行對比和分析。結果兩組患者的冠狀動脈再通率對比觀察組患者在靜脈溶栓後0.5、1 h以及2 h冠狀動脈的再通率分彆33.5%、66%和88.5%,全部明顯高于對照組,差異具有統計學意義(P<0.05)；觀察組患者的血清CK以及(CK-MB峰值的時間為(13.58±2.49)、(11.27±2.4)h,較對照組的酶峰值顯著提前,但是其差異無統計學的意義(P>0.05)；觀察組和對照組患者在靜脈溶栓以後4週內死亡率分彆為4%和7.89%,該兩組患者的死亡率對比,其差異沒有統計學的意義(?2=0.267,P>0.05)。結論對于急性心肌梗死患者,使用藥物瑞替普酶靜脈溶栓,其冠狀動脈的再通率高,酶峰值顯著提前,而且安全可靠。
목적：탐토분석서체보매정맥용전재치료급성심기경사(AMI)중적림상치료효과여안전성。방법선택재2012년7월—2014년6월기간,해원수치적전부부합표준적심기경사환자151례,안수궤원칙분위관찰조75례화대조조76례,대조조환자사용약물뇨격매,이대우관찰조환자,칙급여서체보매정맥용전,연후장량조환자적치료효과진행대비화분석。결과량조환자적관상동맥재통솔대비관찰조환자재정맥용전후0.5、1 h이급2 h관상동맥적재통솔분별33.5%、66%화88.5%,전부명현고우대조조,차이구유통계학의의(P<0.05)；관찰조환자적혈청CK이급(CK-MB봉치적시간위(13.58±2.49)、(11.27±2.4)h,교대조조적매봉치현저제전,단시기차이무통계학적의의(P>0.05)；관찰조화대조조환자재정맥용전이후4주내사망솔분별위4%화7.89%,해량조환자적사망솔대비,기차이몰유통계학적의의(?2=0.267,P>0.05)。결론대우급성심기경사환자,사용약물서체보매정맥용전,기관상동맥적재통솔고,매봉치현저제전,이차안전가고。
Objective To investigate and analysis of reteplase in the treatment of acute myocardial infarction (AMI)clinical therapeutic effect and safety of.Methods To choose from July to 2014 during the period of 2012 June, our hospital all conform to the standards of the myocardial infarction in 151 patients, randomly divided into observation group 75 cases and control group 76 cases, control group with medication of patients with urokinase, and to observe patients, to give a reteplase thrombolytic therapy, and then the two groups patients were treated by comparison and analysis.Results The two groups of patients with coronary artery recanalization rate comparison in the observation group were intravenous thrombolysis after 0.5h,1h and 2h coronary artery recanalization rates were 33.5%,66% and 88.5%, are significantly higher than the control group, the difference has statistics significance (P<0.05);the observation group patients serum CK and CK-MB (peak the time for the (13.58±2.49)h,(11.27±2.4) h, more forward than the control group of the time, but the difference was not statistically significance (P>0.05); the observation group and the control group in the patients with intravenous thrombolytic therapy after 4 weeks of mortality were 4% and 7.89%, compared the mortality of the two groups, the difference was not statistically significance (?2=0.267,P>0.05).Conclusion For patients with acute myocardial infarction, the use of drugs of reteplase, coronary artery recanalization rate, recanalization time can reach, safe and reliable.
